Grant of Options and RSUs, and Issue of Warrants
Summary by AI BETAClose X
8 June 2026
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine", or the "Company")
Grant of Options and RSUs, and Issue of Warrants
Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces the issuance of Restricted Share Units, options and warrants below.
Grant of Restricted Share Units
On 5 June 2026, the Company granted a total of 3,121,471 Restricted Share Units ("RSUs") to employees and executive directors.
The RSUs granted to executive directors of the Company are as follows:
|
Director |
Position |
RSUs granted |
Total RSUs units now held |
|
Carolyn Cross |
CEO |
767,876 |
767,876 |
|
Nicolas Loebel |
CTO |
716,684 |
716,684 |
The Restricted Share Units vest upon receipt of U.S. Food and Drug Administration ("FDA") marketing approval for Ondine's nasal photodisinfection therapy for the reduction of surgical site infections.
Following the grant of the RSUs, the Company has 3,121,471 RSUs to subscribe for new common shares in the Company ("Common Shares") outstanding, which represents c.0.56% per cent of the Company's current issued share capital.
Grant of Options
On 5 June 2026, 8,290,000 Options were granted to employees, executive directors, non-executive directors and consultants.
The Options to the executive and non-executive directors are as follows:
|
Director |
Position |
Options granted |
Total Options now held |
|
Jean Charest |
Non-executive Chair |
400,000 |
740,000 |
|
Jean Duvall |
Non-executive Director |
250,000 |
400,000 |
|
Junaid Bajwa |
Non-executive Director |
250,000 |
400,000 |
|
Margaret Shaw |
Non-executive Director |
250,000 |
325,000 |
|
Carolyn Cross |
Executive Director |
2,000,000 |
4,075,000 |
|
Nicolas Loebel |
Executive Director |
2,000,000 |
11,575,000 |
The new Options all have an exercise price of 13.25 pence, being the closing midmarket share price on 5 June 2026 (the "Approval Date"), the day on which the grant of Options was approved by the Board. The Options vest evenly over a period of three years, with 33.33% vesting on each of the three successive anniversaries of the Approval Date and can be exercised for a period of eight years from the Approval Date.
Following the grant of the new Options, the Company has 26,528,334 Options to subscribe for new Common Shares outstanding, which represents c.4.73% per cent of the Company's current issued share capital.
Issue of Warrants
On 5 June 2026, the Company issued 1,000,000 warrants to an executive, entitling the holder to acquire Common Shares of the Company at a strike price of 15 pence each. The warrants have an expiration date of six months following receipt of U.S. Food and Drug Administration ("FDA") marketing approval for Ondine's nasal photodisinfection therapy for the reduction of surgical site infections.
Following the grant of the warrants, the Company has 1,000,000 warrants to subscribe for new Common Shares outstanding, which represents c.0.18% per cent of the Company's current issued share capital.
Enquiries:
|
Ondine Biomedical Inc. |
ondinebio.com |
|
Carolyn Cross, CEO |
+1 604 669 0555 |
|
|
|
|
Strand Hanson Limited (Nominated & Joint Financial Adviser) |
|
|
James Harris, Richard Johnson, Imogen Ellis |
+44 (0)20 7409 3494 |
|
|
|
|
Peel Hunt LLP (Broker & Joint Financial Adviser) |
|
|
James Steel, Dr. Chris Golden |
+44 (0)20 7418 8900 |
|
|
|
|
5654 & Company (Financial PR and IR Adviser) |
ondinebiomedical@5654.co.uk |
|
Matthew Neal, Chris Gardner, Melissa Gardiner |
+44 0791 7800 011 +44 0775 7697 357 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company focused on the development of light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those associated with multidrug-resistant organisms.
Ondine's lead product, Steriwave®, is authorized for nasal decolonisation in Canada and certain international markets. In the United States, the technology has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration and recently completed enrolment in its Phase 3 clinical trial.
The Company has a pipeline of additional photodisinfection products in various stages of development for application in areas including chronic sinusitis, ventilator-associated pneumonia, burns and other indications.
U.S. Regulatory Status and Clinical Data Disclaimer
Ondine's light-activated antimicrobial technology, commercially available as Steriwave® in certain jurisdictions, is not approved, cleared, or commercially available for sale or clinical use in the United States and is limited by U.S. law to investigational use only.
References to clinical outcomes in this release should be interpreted in the context of the specific studies or real-world evaluations described and do not imply regulatory approval for any particular indication.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund